

07.00	Registration						
08.30 - 10.30	Opening Ceremony & Session A						
08.30 - 08.45	Welcome to the Conference						
08.45 - 08.50	Community Opening						
08.50 - 09.00	Awards						
09.00 - 09.20	Evidence-based approaches for reducing drug-related deaths – What interventions work and what does the future hold? Andrew McAuley, Public Health Scotland / Glasgow Caledonian University, Scotland						
09.20 - 09.40	How can we overcome legal barriers to reduce criminalisation and improve the health of people who use drugs? Niamh Eastwood, Release, UK						
09.40 - 10.00	Questions & Discussion						
10.00 - 10.15	The impact of disruptions to services for people who inject drugs in Ukraine: Modelling the potential impact of Russia's invasion Jack Stone, University of Bristol, UK						
10.15 - 10.30	Implications of using current mechanisms of Opioid Agonist Treatment (OAT) provision to access "Safe Supply" in British Columbia Marion Selfridge, Cool AID Community Health Centre, Canada						
10.30 - 11.00	Coffee Break						
11.00 - 12.30	Plenary Session B						
11.00 - 11.45	Plenary Session led by Garth Mullins from Crackdown Podcast						
11.45 - 12.30	Connecting with Care						
12.30 - 13.00	My Choice: A Participatory Storytelling Project						
13.00 - 14.15	Lunch & Poster Viewing						
13.00 - 14.00	My Choice Photo Exhibition Tour						
14.15 - 15.30	Session C Abstract Session: Reducing harms that may relate to drug use	14.15 - 15.30	Session D Abstract Session: Drug use trends and overdose	14.15 - 15.30	Session E Abstract Session: Infectious diseases	14.15 - 15.30	Session F Abstract Session: COVID-19
14.15 - 14.30	'Safer Supply (SS) and HCV micro-elimination during COVID 19 - Prescribing novel opioid and stimulant alternatives to toxic illicit drug supply in Victoria, British Columbia Marion Selfridge, Cool AID Community Health Centre, Canada	14.15 - 14.30	The impact of opioid agonist treatment on fatal and non-fatal drug overdose among people with a history of opioid dependence in NSW, Australia, 2001-2018: Findings from the OATS retrospective linkage study Nicola Jones, National Drug And Alcohol Research Centre, Australia	14.15 - 14.30	The association between access to opioid substitution therapy and HIV incidence among people who inject drugs (PWID) in Kachin, Myanmar, 2008-2020 Peter Vickerman, University of Bristol, UK	14.15 - 14.30	SARS-CoV-2 vaccine uptake and risks of severe COVID-19 disease among people prescribed opioid agonist therapy in Scotland Alan Yeung, Glasgow Caledonian University, UK
14.30 - 14.45	The global coverage of interventions to prevent and manage drug-related harms among people who inject drugs: A multi-stage systematic review of the evidence Samantha Colledge-Frisby, National Drug Research Institute, Australia	14.30 - 14.45	Barriers to management of opioid withdrawal in hospitals in England: a document analysis of hospital policies Magdalena Harris, London School Of Hygiene And Tropical Medicine, UK	14.30 - 14.45	Social and structural determinants of injecting-related bacterial and fungal infections among people who inject drugs: qualitative systematic review and thematic synthesis Thomas Brothers, Dalhousie University & University College London, UK	14.30 - 14.45	Co-constructing a community-based telemedicine program to meet the needs of vulnerable people with opioid use disorder during COVID-19 Stine Hoj, University of Montreal Hospital Research Centre (CRCHUM), Canada
14.45 - 15.00	A novel contingency management intervention in the context of a syndermic of drug-related harms in Glasgow: First year of the 'WAND' initiative Shanley Smith, Glasgow Caledonian University / Public Health Scotland, UK	14.45 - 15.00	Age and chronic disease-specific associations between opioid agonist treatment and opioid overdose death by age and chronic disease status: Cohort study using linked administrative health data in New South Wales, Australia, 2001-2018 Sarah Larney, Université De Montréal, Canada	14.45 - 15.00	Models of good practice interventions to enhance the infectious disease care cascade among people who inject drugs: A qualitative study Tanja Schwarz, Austrian National Public Health Institute (GOEG), Austria	14.45 - 15.00	"We weren't just breaking the law by taking drugs, we were breaking the law by simply being together": a qualitative study of people engaged in opioid agonist treatment as a counterpublic during the COVID-19 pandemic in Australia Anna Conway, Kirby Institute, UNSW, Australia
15.00 - 15.05	The safety and utility of benzodiazepine (bzd) prescribing among people receiving ort in Scotland: analysis of a national dataset over 11 years Catriona Matheson, University of Stirling, UK	15.00 - 15.05	Binge drug injection among people who inject drugs in Montreal: characterizing the substances and social contexts involved to inform prevention efforts Nanor Minoyan, CRCHUM / Université de Montréal, Canada	15.00 - 15.05	Major Barriers and Facilitators to Transitions of Care for Patients Hospitalized with Infectious Complications of Opioid Use Disorder: A Multi-site, Qualitative Analysis of Expert Stakeholders Sarah Kattakuzhy, Institute of Human Virology at the University of Maryland, USA	15.00 - 15.05	Factors associated with SARS-COV-2 infection and severe COVID-19 disease among individuals prescribed opioid agonist treatment in Scotland Megan Glancy, Glasgow Caledonian University/public Health Scotland, UK
15.05 - 15.10	"Why would we not want to keep everybody safe?" Views of family members of people who use drugs and strategic decisions makers on the implementation of drug consumption rooms in Scotland Tracey Price, University of Stirling, UK	15.05 - 15.10	Longitudinal associations of anxiety and depression among people who primarily smoke methamphetamine Zoe Duncan, Monash University, Australia	15.05 - 15.10	High levels of HCV transmission and a new outbreak of HIV infection during the COVID-19 pandemic among people who inject drugs in Thessaloniki, Greece Sotirios Roussos, National and Kapodistrian University of Athens, Greece	15.05 - 15.10	Impacts of COVID-19 on people who use and inject drugs in Australia Shelley Walker, Burnet Institute, Australia
15.10 - 15.15	A qualitative exploration of three hypothetical models of drug checking service delivery in a Scottish context Danilo Falzon, University of Stirling, UK	15.10 - 15.15	Increased risk of non-fatal overdose associated with NPS-type ['street'] benzodiazepine use in Scotland, UK Andrew McAuley, Glasgow Caledonian University, UK	15.10 - 15.15	Population-based study of skin and soft tissue infection incidence in people who use drugs in Norway Olav Dalgard, Akershus University Hospital, Norway	15.10 - 15.15	Police as advocates of harm reduction during COVID-19 Michael Wilson, Advance Access & Delivery SA, South Africa
15.15 - 15.20	Knowledge and diffusion of take-home naloxone among people who use opioids in France Salim Mezaache, Marseille University Hospitals, France	15.15 - 15.20	Shifts in common causes of death among adults with opioid use disorders - A retrospective Swiss opioid agonist treatment cohort study over 22 years Philip Bruggmann, Arud, Centre for Addiction Medicine, Switzerland	15.15 - 15.20	Restore: A peer facilitated model for substance use disorder care integration into outpatient infectious disease care Oluwaseun Falade-Nwulia, Johns Hopkins University School of Medicine, USA	15.15 - 15.20	Evaluation of an emergency safe supply drugs and managed alcohol program in COVID-19 isolation hotel shelters for people experiencing homelessness Thomas Brothers, Dalhousie University & University College London, UK
15.20 - 15.25	Economic evaluation of syringe vending machines in Tbilisi, Georgia Josephine Walker, University Of Bristol, UK	15.20 - 15.25	Exploring the lived experience of drug-induced overdose through peer-led interviews Amy Malaguti, NHS Tayside / University of Dundee	15.20 - 15.25	Same-day testing and treatment of sexually transmitted infections among female sex workers who use drugs using nucleic acid amplification testing at a point-of-care mobile unit Jorge Valencia, Hospital Universitario Infanta Leonor, Spain	15.20 - 15.25	Modified map in COVID quarantine Bronwyn Gordon, Drug & Alcohol Services SA, Australia
15.25 - 15.30	Impacts of an overdose prevention service on overdose incidents in a Canadian federal penitentiary Shannon Thompson, Correctional Service, Canada	15.25 - 15.30	Preliminary results from a randomized controlled trial of an integrated care model of infectious disease management and long-acting injectable buprenorphine for patients hospitalized with infections and opioid use disorder Sandra Springer, Yale School of Medicine, USA	15.25 - 15.30	An evaluation of the health impact of injecting drug use on acute secondary care services: The east of Scotland experience Caitlin Macleod, NHS Tayside, UK	15.25 - 15.30	Prolonged Dam-Take-Home in times of COVID-19: Harm reduction or increase? Franciska Brezan, Arud Centres for Addiction Medicine, Switzerland
15.30 - 16.15	Coffee Break & Poster Tour						
15.40 - 16.05	Poster Tour 01: Key Populations			15.40 - 16.05	Poster Tour 02: Data, Data, Data		
15.40 - 15.45	The Hepatitis Engagement Program (HEP): Towards the elimination of Hepatitis C vertical transmission in New Brunswick, Canada Katie Harland, Centre For Research, Education, And Clinical Care Of At-risk Populations, Canada			15.40 - 15.45	Geographic clustering of social injection activity and risk of hepatitis C virus acquisition among people who inject drugs in Montreal Nanor Minoyan, CRCHUM / Université de Montréal, Canada		
15.45 - 15.50	Reducing the Time-To-Treatment for patients with HCV in English remand prisons Arran Ludlow Rhodes, Practice Plus Group, UK			15.45 - 15.50	Phylogenetic transmission clusters of Hepatitis C virus among people who use drugs who access harm reduction services in three South African cities, 2016 – 2017 Nkosenhle Ndlovu, University of the Witwatersrand, South Africa		
15.50 - 15.55	Impact of HCV testing and treatment services on HCV transmission among men who have sex with men and inject drugs in San Francisco: A modelling analysis Adelina Arteni, University of Bristol, UK			15.50 - 15.55	Drug dependence and Hepatitis C RNA testing and treatment in the era of direct-acting antiviral therapy among people with a Hepatitis C notification in New South Wales, Australia Mohammad Tahir Yousafzai, The Kirby Institute, UNSW Sydney, Australia		
15.55 - 16.00	Higher incidence of HCV re-infection among treatment experienced people who inject drugs in Tayside, Scotland. Christopher Byrne, University of Dundee, UK			15.55 - 16.00	Development and validation of a global model to optimize HIV resource allocation among people who inject drugs: The intrepid model Natasha Martin, University of California San Diego, USA		
16.00 - 16.05	Modelling the impact of the care cascade amongst young people who inject drugs in San Francisco Hannah Fraser, University Of Bristol, UK			16.00 - 16.05	The benefits of a regional collaborative drug related death review and surveillance system: Insights from implementation in the north west of England Howard Reed, Public Health Institute, Liverpool John Moores University, UK		
16.15 - 17.45	Session G: Drug treatment	16.15 - 17.45	Session H: C-EHRN - Boosting communities and increasing impact: the need for scaling up community-based HCV prevention, treatment and linkage to care services for PWUD	16.15 - 17.45	Session I: Other Infections	16.15 - 17.45	Session J: Moving forward towards broader implementation of "Safe Supply"
17.45 - 19.00	Welcome Reception & Poster Viewing						

07.30	Registration						
08.00 - 08.45	Industry Sponsored Morning Symposium						
09.00 - 10.45	Session K						
09.00 - 09.20	HCV elimination among people who inject drugs – Where are we now and where to from here? Natasha Martin, University of California, San Diego, United States						
09.20 - 09.55	Real-world examples of success in achieving HCV elimination among people who inject drugs Speaker, Institution, Country						
09.55 - 10.15	Questions & Discussion						
10.15 - 10.30	Changes in self-reported quality of life associated with successful DAA Hepatitis C treatment in people who use drugs Scott McDonald, Glasgow Caledonian University, UK						
10.30 - 10.45	Opportunistic treatment of Hepatitis C infection: A randomized controlled trial of immediate treatment initiation among hospitalized people who inject drugs (Opportuni-C) Håvard Midgard, Akershus University Hospital, Norway						
10.45 - 11.15	Coffee Break						
11.15 - 12.15	Informing elimination strategies and harm reduction policies through bio-behavioural surveys among people who inject drugs	11.15 - 12.15	Peer Involvement in Research	11.15 - 12.15	Nurses Session	11.15 - 12.15	Prevention and control of HCV and HIV among people who inject drugs in 2022 and beyond: new evidence and key recommendations within the updated public health guidance ECDC/EMCDDA
12.15 - 14.00	Lunch and Poster Viewing						
12.45 - 13.45	Industry Sponsored Lunch Symposium:						
14.00 - 15.00	Session N: Oral Abstract Session	14.00 - 15.00	Session M: Oral Abstract Session	14.00 - 15.00	Session N Abstract Session: Prisons	14.00 - 15.00	Session O: Oral Abstract Session
14.00 - 14.15	A novel Hepatitis C intervention in Denmark to test and treat people who inject drugs. Jeffrey Lazarus, ISGlobal, Spain	14.00 - 14.15	Recruitment and treatment of social-injecting networks in the treatment and prevention study: A real-world social network design community-based trial of direct-acting antivirals for Hepatitis C among people who inject drugs. Brendan Harney, Burnet Institute, Australia	14.00 - 14.15	Comprehensive HCV service delivery model for achieving micro-elimination of Hepatitis C among the incarcerated population of Haryana and Chandigarh, India. Kanudeep Kaur, FIND, India	14.00 - 14.15	Evaluating the impact of direct-acting anti-viral therapy on Hepatitis C Viraemia among people who inject drugs. Pantelis Samartsidis, University of Cambridge, UK
14.15 - 14.30	Two randomized controlled trials to measure the impact of HCV self-testing in key populations in Georgia and Malaysia Sonjelle Shilton, FIND, Switzerland	14.15 - 14.30	Innovative community-based strategy to eliminate HCV among people who inject drugs in Vietnam Nicolas Nagot, University of Montpellier, France	14.15 - 14.30	Micro-eliminating HCV in 8 diverse prisons that serve a general population of 3.7 million in the Yorkshire region of England. Nichola Royal, Practice Plus Group Ltd, UK	14.15 - 14.30	Changing Trends in Hepatitis C Reinfection Rates Following the Scale-Up of Direct-Acting Antivirals Among People Who Inject Drugs in Scotland Norah Palmateer, Glasgow Caledonian University, UK
14.30 - 14.45	Implementation of dried blood spot testing for HIV and Hepatitis C: The NSW DBS pilot study: A client-centred alternative to traditional health care Nigel Carrington, NSW Ministry Of Health/Sydney Sexual Health Centre, Australia	14.30 - 14.45	Understanding attitudes and concerns regarding the use of molecular cluster detection as a Hepatitis C elimination strategy: A qualitative study of persons who inject drugs. Matthew Lambert, University of Wisconsin - Madison School of Medicine and Public Health, USA	14.30 - 14.45	Hepatitis C micro-elimination program in prisons across Greece: "Access4All in Greek Prisons" George Kalamitsis, Hellenic Liver Patients Association "Prometheus", Greece	14.30 - 14.45	Excess mortality risk among Hepatitis C patients after being "cured" in the interferon-free era: Results from three population-based cohorts Victoria Hamill, Glasgow Caledonian University, UK
14.45 - 14.50	HCV RNA Point-of-Care testing to measure HCV prevalence and incidence among service users of an integrated supervised consumption service in Toronto, Canada Kate Mason, Toronto Community Hep C Program, Canada	14.45 - 14.50	Interventions to improve HCV care for people who inject drugs: A systematic review and meta-analysis Evan Cunningham, Kirby Institute, Australia	14.45 - 14.50	Trust and service engagement among people who inject drugs post-release Lise Lafferty, UNSW Sydney, Australia	14.45 - 14.50	Sustained reduction in active HCV infection in people seeking addiction treatment at the National Center of Addiction Medicine (Vogur Hospital) in Iceland Ragnheidur Fridriksdottir, National Center Of Addiciton Medicine - SAA, Iceland
14.50 - 14.55	Acceptability, Appropriateness, and Feasibility of An On-Site HCV "Test and Treat" Strategy at Opioid Treatment Programs in North America Oluwaseun Falade-Nwulia, Johns Hopkins University School Of Medicine, USA	14.50 - 14.55	Factors associated with stigma, discrimination, and negative health care treatment among people who inject drugs: The ETHOS Engage Study Timothy Broady, Centre For Social Research In Health, Unsw, Australia	14.50 - 14.55	Barriers and facilitators to implementing Point-Of-Care RNA testing for Hepatitis C virus in a Scottish prison health centre. Christopher Byrne, University Of Dundee, UK	14.50 - 14.55	"Treated like a Human Being": Perspectives of people who inject drugs attending low-threshold HCV treatment at a syringe service program in New York City. Shashi Kapadia, Weill Cornell Medicine, USA
14.55 - 15.00	Peer and nursing-led outreach combined with Point-of-Care HCV testing to decentralise HCV care and enhance HCV treatment among people who use drugs, people who experience homelessness, and migrants: The Reach U Project Cristiana Merendeiro, CRESCER - Community Intervention Association, Portugal	14.55 - 15.00	The Role and Importance of Community-Led Values & Preferences Research in Developing Models of Care for People Who Use Drugs Annie Madden, International Network Of People Who Use Drugs (INPUD), Australia	14.55 - 15.00	Identifying barriers and enablers to opt-out Hepatitis C virus screening in provincial prisons in Quebec, Canada: A qualitative study with correctional stakeholders using the consolidated framework for implementation research. Guillaume Fontaine, Centre for Implementation Research, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Canada	14.55 - 15.00	Characterizing the Hepatitis C virus cascade of care for First Nations individuals in Ontario, Canada Andrew Mendlowitz, Toronto Centre for Liver Disease, Canada
				15.10 - 15.15	Curing the "Hard to Reach" Rachael Bryett, Hepatitis Queensland, Australia		
15.15 - 15.45	Coffee Break and Poster Tour						
15.45 - 17.15	Session P: Interventions to reduce drug-related harms	16.15 - 17.45	Session Q: HCV	16.15 - 17.45	Session R: WHO Session	16.15 - 17.45	Session S: EMCR - How to write a successful manuscript
19:00 - 23:00	Conference Dinner						

09.30 - 11.00	Session T													
09.30 - 09.50	Community-led models for improving the health of people who use drugs – Successes, challenges and where to next Magdalena Harris, London School of Hygiene and Tropical Medicine, UK													
09.50 - 10.10	How do we address the broader social and health issues among people who inject drugs? Dame Carol Black, Institution, UK													
10.10 - 10.30	Questions & Discussion													
10.30 - 10.45	Health benefits and public order improvements after the implementation of DCRs in France. Results from the COSINUS cohort survey Marie Jauffret-Roustide, Inserm, France													
10.45 - 11.00	Evaluating the impact and cost-effectiveness of a novel police education program on HIV and overdose among people who inject drugs in Tijuana, Mexico Javier Cepeda, Johns Hopkins Bloomberg School of Public Health, USA													
11.00 - 11.45	Coffee Break & Poster Tour													
11.10 - 11.35	Poster Tour 03: Integrated Care Strategies/Models			11.10 - 11.35	Poster Tour 04: Reducing Drug-Related Harms									
11.10 - 11.15	Dry Blood Spot Polymerase Chain Reaction (DBS PCR) Blood Borne Virus (BBV) Testing in the setting of police custody. Stuart Gallacher, NHS Greater Glasgow and Clyde, UK			11.10 - 11.15	The impact of COVID-19 in the consumption patterns of people who inject drugs Joana Pires, Médicos Do Mundo, Portugal									
11.15 - 11.20	Evaluation of a naloxone pilot among police officers in Scotland: a public health approach to policing Elizabeth Speakman, Edinburgh Napier University, UK			11.15 - 11.20	Overlapping adverse health outcomes among people who inject drugs in England, Wales and Northern Ireland, 2019-2020 Claire Edmundson, UK Health Security Agency, UK									
11.20 - 11.25	Integrated medically assisted therapy clinic for people who use drugs, a case of Karuri Clinic, Kiambu County, Kenya Angela Thiongo, Medecins Sans Frontieres, Kenya			11.20 - 11.25	A systematic review of psychosocial factors associated with risk of drug-related overdose Amy Malaguti, NHS Tayside / University of Dundee, UK									
11.25 - 11.30	Rapid Hepatitis C Treatment Initiation in Young People who Inject Drugs: Final Results From The HCV-Seek, Test & Rapid Treatment (HCV-ST&RT) Randomized Pilot Clinical Trial. Benjamin Eckhardt, NYU School of Medicine/Bellevue Hospital, USA			11.25 - 11.30	Piloting a digital health respiratory monitoring intervention to reduce drug-related deaths – The 'RESCU' project Kristina Hnizdilová, University of Dundee, UK									
11.30 - 11.35	Evaluation of Universal Hepatitis C Screening and Treatment among Psychiatry Inpatients Erin Mandel, University Health Network, Canada			11.30 - 11.35	Promoting community naloxone provision; utilising people with lived experience to address Drug Related Deaths within Dundee Daniel Kelly, Hillcrest Futures, UK									
11.45 - 12.45	Session U Abstract Session: Equity and identity		11.45 - 12.45	Session V: Oral Abstract Session		11.45 - 12.45	Session W: Oral Abstract Session		11.45 - 12.45	Session X: Oral Abstract Session				
11.45 - 12.00	Are we leaving women who inject drugs behind on the 'road to hepatitis C elimination'? A qualitative exploration to minimise inequalities in health. Alison Marshall, The Kirby Institute, Australia		11.45 - 12.00	Outcomes of community-led HCV and HBV care model in India, including same-day HCV "Test and Treat" to facilitate micro-elimination Nalinikanta Rajkumar, Community Network For Empowerment (CoNE), India		11.45 - 12.00	Effect of integrated treatment of Hepatitis C virus infection on treatment initiation and sustained virologic response among people who inject drugs: A multi-center randomized controlled trial (Intro-HCV) Lars T. Fadnes, Haukeland University Hospital, Norway		11.45 - 12.00	Accelerating Hepatitis C treatment initiation in people who inject drugs from remote areas via resource and network sharing among primary care centers in Malaysia Huan-keat Chan, Clinical Research Center, Sultanah Bahiyah Hospital, Malaysia				
12.00 - 12.15	Unstable housing may be a major obstacle on the road to HCV elimination. Results from the treatment as prevention (TraP HepC) program in Iceland. Sigurdur Olafsson, Landspítali University Hospital, Iceland		12.00 - 12.15	Accessible HCV care for people who inject drugs: Randomized clinical trial comparing low-threshold treatment at a syringe service program versus facilitated referral. Benjamin Eckhardt, NYU School of Medicine/Bellevue Hospital, USA		12.00 - 12.15	Development of a Calgary inner-city HCV network to support Hepatitis C screening, treatment and linkage to care for priority populations Nicola Gale, Cups Liver Clinic, Canada		12.00 - 12.15	The role of adherence support in achieving HCV cure among people who inject drugs accessing harm reductions settings in Kenya Mercy Nyakowa, National AIDS and STI Control Program, Kenya				
12.15 - 12.30	An adaptive approach and community-led model to enable access to treatment and cure Hepatitis C in rural and indigenous communities for people who inject drugs in Saskatchewan, Canada Stuart Skinner & Cara Spence, Wellness Wheel, Canada		12.15 - 12.30	Hepatitis C treatment uptake following a Hepatitis C Point-of-Care testing "Blitz" at a prison in Queensland, Australia: The Woodford Prison testing campaign Mim O'Flynn, Kombi Clinic Ltd, Australia		12.15 - 12.30	National direct acting antiviral treatment and retreatment discontinuation in Australia Joanne Carson, The Kirby Institute, UNSW Sydney, Australia		12.15 - 12.30	Changing attitudes of the general public towards people with prison and injecting drug use histories: A research-informed, co-designed, arts-based intervention Carla Treloar, UNSW, Australia				
12.30 - 12.35	Factors associated with Hepatitis C virus treatment uptake among females with drug dependence in the direct acting antiviral era in New South Wales, Australia Heather Valerio, The Kirby Institute, Australia		12.30 - 12.35	Implementing Community-Based Models of Hepatitis C Care to Achieve Elimination: The Tasmanian Eliminate Hepatitis C Australian Outreach Project Joshua Dawe, Burnet Institute, Australia		12.30 - 12.35	HCV treatment uptake among people who inject drugs in Oslo: A registry-based study. Kristian Malme, Akershus University Hospital, Switzerland		12.30 - 12.35	Community-based HCV therapy with Sofobuvir and Velpatasvir in the inner city. Brian Conway, Vancouver Infectious Diseases Centre, Canada				
12.35 - 12.40	Making gender more visible in research and policy on drugs and violence David Moore, La Trobe University, Australia		12.35 - 12.40	Meeting people where they are at: Preliminary results from the evaluation of HEP@HOME, a mobile outreach program targeting people who inject drugs and who have reduced access to mainstream Hepatitis C (HCV) health services Phillip Read, Kirketon Road Centre, Australia		12.35 - 12.40	Non-uptake of treatment for Hepatitis C in the antiviral era: A qualitative analysis Suzanne Fraser, Australian Research Centre In Sex, Health And Society, La Trobe University, Australia		12.35 - 12.40	End Hep C SF and the power of collective impact Katie Burk, Facente Consulting, USA				
12.40 - 12.45	"Protective, Private, Proud": Identity matters for gay and bisexual men who inject drugs in Australia Sophia E Schroeder, Burnet Institute, Australia		12.40 - 12.45	HepCURE™ HCV model of care – Successes and learnings from our collective efforts in screening and linkage to care activities during the COVID-19 pandemic Christian Marcoux, HepCURE™, Canada		12.40 - 12.45	Evaluating the cost-effectiveness of integrated treatment for Hepatitis C virus among people who inject drugs in Norway. Aaron G Lim, University Of Bristol, UK		12.40 - 12.45	Wessex Clinical Vans Louise Hansford, Inclusion, UK				
12.45 - 14.15	Lunch													
TBC	INHSU Prisons session													
14.15 - 15.45	Session Y: Beyond Infections			14.15 - 15.45	Session Z: Global systematic reviews of injecting and harm reduction coverage			14.15 - 15.45	Session ZA: New Innovations to Control HIV Transmission Among PWID			14.15 - 15.45	Session ZB: 4 Nations	
15.45 - 16.15	Coffee Break													
16.15 - 17.15	Conference Closing													
16.00 - 16.10	Community Rapporteur													
16.10 - 16.20	Epidemiology & Public Health Rapporteur													
16.20 - 16.40	Clinical Science Rapporteur													
16.40 - 16.50	Models of Care Rapporteur													
16.50 - 17.00	Social Science & Policy Rapporteur													
17.00 - 17.10	Conference Closing and Introduction of Upcoming Conference													